Global Proteomics Partnering Terms and Agreements 2014 to 2019

The Global Proteomics Partnering Terms and Agreements 2014 to 2019 report provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies.

 

Trends in Proteomics partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Proteomics partnering contract documents
Top Proteomics deals by value

 

The Global Proteomics Partnering Terms and Agreements report provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter Proteomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Proteomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

This report contains links to online copies of actual Proteomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How are sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

 

The initial chapters of this report provide an orientation of Proteomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Proteomics dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading Proteomics deals since 2014. Deals are listed by headline value, signed by big pharma, most active Proteomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
 

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Proteomics dealmaking with a brief summary followed by a comprehensive listing of Proteomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
 

Chapter 5 provides a comprehensive and detailed review of Proteomics partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
 

Chapter 7 provides a comprehensive and detailed review of Proteomics partnering deals signed and announced since Jan 2014. The chapter is organized by specific Proteomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided organized by Proteomics partnering company A-Z, deal type definitions and Proteomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Proteomics partnering and dealmaking since 2014.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Proteomics technologies and products.

 

Report scope

Global Proteomics Partnering Terms and Agreements 2014 to 2019 is intended to provide the reader with an in-depth understanding and access to Proteomics trends and structure of deals entered into by leading companies worldwide.

 

Global Proteomics Partnering Terms and Agreements 2014 to 2019 includes:

Trends in Proteomics dealmaking in the biopharma industry since 2014
Analysis of Proteomics deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Proteomics deals
Access to over 140 Proteomics deal records and contract documents where available
The leading antibody deals by value since 2014
Most active Proteomics dealmakers since 2014
The leading Proteomics partnering resources

 

In Global Proteomics Partnering Terms and Agreements 2014 to 2019, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Proteomics dealmaking

2.1. Introduction
2.2. Proteomics partnering over the years
2.3. Most active Proteomics dealmakers
2.4. Proteomics partnering by deal type
2.5. Proteomics partnering by therapy area
2.6. Proteomics partnering by industry sector
2.7. Deal terms for Proteomics partnering
2.7.1 Proteomics partnering headline values
2.7.2 Proteomics deal upfront payments
2.7.3 Proteomics deal milestone payments
2.7.4 Proteomics royalty rates
2.8. The anatomy of an Proteomics deal
2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 – Leading Proteomics deals

3.1. Introduction
3.2. Top Proteomics deals by value

Chapter 4 – Most active Proteomics dealmakers

4.1. Introduction
4.2. Most active Proteomics dealmakers
4.3. Most active Proteomics partnering company profiles

Chapter 5 – Proteomics contracts dealmaking directory

5.1. Introduction
5.2. Proteomics contracts dealmaking directory

Chapter 6 – Proteomics dealmaking by technology type

Chapter 7 – Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 – Proteomics deals by company A-Z
Appendix 2 – Proteomics deals by stage of development
Appendix 3 – Proteomics deals by deal type
Appendix 4 – Proteomics deals by therapy area
Appendix 5 –Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Proteomics partnering since 2014
Figure 2: Active Proteomics dealmaking activity sincce 2014
Figure 3: Proteomics partnering by deal type since 2014
Figure 4: Proteomics partnering by disease type since 2014
Figure 5: Proteomics partnering by industry sector since 2014
Figure 6: Proteomics deals with a headline value
Figure 7: Proteomics deals with an upfront value
Figure 8: Proteomics deals with a milestone value
Figure 9: Proteomics deals with a royalty rate value
Figure 10: Top Proteomics deals by value since 2014
Figure 11: Most active Proteomics dealmakers since 2014
Figure 12: Proteomics partnering by technology type since 2014
Figure 13: Online partnering resources
Figure 14: Forthcoming partnering events
 


2020 Global Virology and Bacteriology Market for over 100 Tests: US, Europe, Japan--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Emerging Technologies, Instrumentation, Opportunities

This new report is a seven-country strategic analysis of major business opportunities emerging in the infectious disease testing market during the next five years. The report examines key trends in the U.S.,

USD 28500 View Report

2020 Global Transfusion Medicine Market for Over 40 Immunohematology and NAT Tests: Supplier Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for Suppliers

This comprehensive seven-country report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global transfusion diagnostic market during the next five years,

USD 18500 View Report

Global Proteomics Instrument Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Proteomics Instrument is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end

USD 4000 View Report

Global Proteomics Workcell Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Proteomics Workcell is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end

USD 4000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available